Clinical Trial Detail

NCT ID NCT00576654
Title Irinotecan Hydrochloride and Veliparib in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements yes
Sponsors National Cancer Institute (NCI)
Indications

triple-receptor negative breast cancer

Hodgkin's lymphoma

non-Hodgkin lymphoma

Advanced Solid Tumor

Therapies

Irinotecan

Veliparib

Age Groups: adult

Additional content available in CKB BOOST